Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": An international, multicenter poststudy survey (ProREAL)

Archives of Internal Medicine

Volumn 172, Issue 9, 2012, Pages 715-722

  Albrich, Werner C ^a   Dusemund, Frank ^a   Bucher, Birgit ^a   Meyer, Stefan ^a   Thomann, Robert ^b,c   Kühn, Felix ^d   Bassetti, Stefano ^d   Sprenger, Martin ^e   Bachli, Esther ^e   Sigrist, Thomas ^f   Schwietert, Martin ^g   Amin, Devendra ^h   Hausfater, Pierre ⁱ   Carre, Eric ^l   Gaillat, Jacques ^j   Schuetz, Philipp ^k   Regez, Katharina ^a   Bossart, Rita ^a   Schild, Ursula ^a   Mueller, Beat ^a  

^a Medical University Department   (Switzerland)

^b Division of Medicine   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Division of Medicine   (Switzerland)

^e Division of Medicine   (Switzerland)

^f Klinik Barmelweid   (Switzerland)

^g Kantonsspital Liestal   (Switzerland)

^h Morton Plant Hospital   (United States)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j Centre Hospitalier de la Region d'Annecy   (France)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN;

ABDOMINAL PAIN; ADULT; AGED; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIARRHEA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FOLLOW UP; FRANCE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWITZERLAND; TREATMENT DURATION; UNITED STATES;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-BACTERIAL AGENTS; CALCITONIN; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS; SWITZERLAND; TREATMENT OUTCOME;

EID: 84861158484     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.770     Document Type: Article

References (31)

1. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9-19. (Pubitemid 46122969)
2. Schuetz P, Christ-Crain M, Wolbers M, et al; ProHOSP Study Group. Procalcitonin-guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007;7:102.
3. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84-93. (Pubitemid 43955248)
4. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600-607. (Pubitemid 38264177)
5. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000-2008.
6. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498-505. (Pubitemid 351442188)
7. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066.
8. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204. (Pubitemid 17009877)
9. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients'exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463-474.
10. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009;34(6):1364-1375.
11. Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83.
12. Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections: hope for hype? Swiss Med Wkly. 2009;139(23-24):318-326.
13. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601-607.
14. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551. (Pubitemid 39025171)
15. Schuetz P, Batschwaroff M, Dusemund F, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis. 2010;29(3):269-277.
16. Schuetz P, Christ-Crain M, Huber AR, Müller B. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor and VIDAS automated immunoassays. Clin Biochem. 2010;43(3):341-344.
17. Hausfater P, Brochet C, Freund Y, Charles V, Bernard M. Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays. Clin Chem Lab Med. 2010;48(4):501-504.
18. Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. (Pubitemid 36560938)
19. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. (Pubitemid 27044625)
20. Kristoffersen KB, Søgaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission: a randomized trial. Clin Microbiol Infect. 2009;15(5):481-487.
21. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther. 2010;8(5):575-587.
22. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171(15):1322-1331.
23. Meisner M, Schmidt J, Hüttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med. 2000;26(suppl 2):S212-S216. (Pubitemid 30186585)
24. Müller F, Christ-Crain M, Bregenzer T, et al; ProHOSP Study Group. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-129.
25. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol. 2011;135(2):182-189.
26. van Nieuwkoop C, Bonten TN, van't Wout JW, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care. 2010;14(6):R206.
27. Aujesky D, McCausland JB, Whittle J, Obrosky DS, Yealy DM, Fine MJ. Reasons why emergency department providers do not rely on the Pneumonia Severity Index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis. 2009;49(10):e100-e108.
28. Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply-resistant cocci: do international comparisons help? Lancet Infect Dis. 2001;1(4):251-261. (Pubitemid 33586057)
29. Harbarth S, Albrich W, Brun-Buisson C. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg Infect Dis. 2002;8(12):1460-1467. (Pubitemid 36008785)
30. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis. 2004;10(3):514-517. (Pubitemid 38314485)
31. Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy. 2006;78(1):77-92. (Pubitemid 44108323)